XLO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
XLO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the three months ended in Mar. 2024, Xilio Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Xilio Therapeutics gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.
The historical data trend for Xilio Therapeutics's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xilio Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Cash Flow from Investing | -0.72 | -2.19 | -1.10 | -1.87 | -0.49 |
Xilio Therapeutics Quarterly Data | |||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Flow from Investing | Get a 7-Day Free Trial | -0.17 | -0.32 | - | - | - |
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Xilio Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:
Xilio Therapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xilio Therapeutics (NAS:XLO) Cash Flow from Investing Explanation
Cash flow from investing contains nine items:
1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.
Xilio Therapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Xilio Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.
Xilio Therapeutics's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Xilio Therapeutics gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Xilio Therapeutics's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Xilio Therapeutics spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Xilio Therapeutics's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Xilio Therapeutics gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Xilio Therapeutics's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Xilio Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Xilio Therapeutics's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Xilio Therapeutics gained $0.00 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Xilio Therapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Xilio Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Xilio Therapeutics's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Xilio Therapeutics paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Xilio Therapeutics's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Xilio Therapeutics paid $0.00 Mil for other investing activities.
Thank you for viewing the detailed overview of Xilio Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Atlas Venture Fund Xi, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Katarina Luptakova | officer: Chief Medical Officer | C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451 |
Christopher James Frankenfield | officer: Chief Operating Officer | C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451 |
Kevin M. Brennan | officer: SVP, FINANCE AND ACCOUNTING | C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451 |
Edward C English | officer: Principal Accounting Officer | 828 WINTER STREET, WALTHAM MA 02451 |
Tomas J. Heyman | director | C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Robert W. Ross | director | C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139 |
Yuan Xu | director | C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080 |
Bain Capital Life Sciences Fund Ii, L.p. | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Atlas Venture Opportunity Fund I, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Sv7 Impact Medicine Fund Lp | 10 percent owner | 71 KINGSWAY, LONDON X0 WC2B 6ST |
Bcls Ii Investo (gp), Llc | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Bcls Ii Investco, Lp | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Bain Capital Life Sciences Investors Ii, Llc | 10 percent owner | 200 CLARENDON STREET, BOSTON MA 02116 |
Rivervest Venture Fund Iv, L.p. | 10 percent owner | 101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-07-2022
By sperokesalga sperokesalga • 05-09-2023
By GuruFocusNews GuruFocusNews • 06-26-2022
By Marketwired • 09-27-2023
By Marketwired • 09-05-2023
By Marketwired • 08-14-2023
By GuruFocusNews GuruFocusNews • 06-16-2022
By sperokesalga sperokesalga • 02-27-2023
By GlobeNewswire • 09-27-2023
By GuruFocusNews GuruFocusNews • 06-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.